- Home
- CAPR vs VYGR Comparison
CAPR vs VYGR Comparison
Compare CAPR & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- VYGR
- Stock Information
- Founded
- CAPR 2005
- VYGR 2013
- Country
- CAPR United States
- VYGR United States
- Employees
- CAPR N/A
- VYGR N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- CAPR Health Care
- VYGR Health Care
- Exchange
- CAPR Nasdaq
- VYGR Nasdaq
- Market Cap
- CAPR 332.5M
- VYGR 386.1M
- IPO Year
- CAPR N/A
- VYGR 2015
- Fundamental
- Price
- CAPR $17.79
- VYGR $5.43
- Analyst Decision
- CAPR Strong Buy
- VYGR Strong Buy
- Analyst Count
- CAPR 7
- VYGR 8
- Target Price
- CAPR $39.29
- VYGR $17.00
- AVG Volume (30 Days)
- CAPR 1.1M
- VYGR 583.2K
- Earning Date
- CAPR 11-13-2024
- VYGR 11-12-2024
- Dividend Yield
- CAPR N/A
- VYGR N/A
- EPS Growth
- CAPR N/A
- VYGR N/A
- EPS
- CAPR N/A
- VYGR 0.47
- Revenue
- CAPR $23,228,045.00
- VYGR $163,784,000.00
- Revenue This Year
- CAPR N/A
- VYGR N/A
- Revenue Next Year
- CAPR $135.53
- VYGR N/A
- P/E Ratio
- CAPR N/A
- VYGR $11.65
- Revenue Growth
- CAPR 65.33
- VYGR 3.40
- 52 Week Low
- CAPR $2.90
- VYGR $5.19
- 52 Week High
- CAPR $23.40
- VYGR $11.72
- Technical
- Relative Strength Index (RSI)
- CAPR 47.77
- VYGR 34.18
- Support Level
- CAPR $17.21
- VYGR $5.19
- Resistance Level
- CAPR $19.47
- VYGR $5.59
- Average True Range (ATR)
- CAPR 1.64
- VYGR 0.41
- MACD
- CAPR -0.38
- VYGR -0.19
- Stochastic Oscillator
- CAPR 28.33
- VYGR 10.71
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.